uniQure NV (QURE) Received its Third Buy in a Row

After Piper Jaffray and B.Riley FBR gave uniQure NV (NASDAQ: QURE) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros reiterated a Buy rating on uniQure NV today and set a price target of $81. The company’s shares opened today at $58.92.

Piros wrote:

“: We reiterate our OW rating and $81 12-month price target on QURE. This morning, uniQure announced updated results from the Phase 2b study of AMT-061 in hemophilia B. The results will be presented as a poster this evening at the Hemostastis & Thrombosis Research Society Symposium. Results showed increased factor IX (FIX) activity up to 57% of normal (47% mean) at six months post-administration for the three patients. In our view, these results are remarkable, given that all three patients had <1% of FIX activity prior to receiving the gene therapy. None of the patients reported bleeding events, or received factor infusions."

According to TipRanks.com, Piros is a 1-star analyst with an average return of -0.9% and a 45.8% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $78.67 average price target, a 33.5% upside from current levels. In a report issued on April 30, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $69.60 and a one-year low of $21.98. Currently, uniQure NV has an average volume of 559.2K.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.